- S&W Seed Co (NASDAQ:SANW) reported second-quarter FY23 sales growth of 2.4% year-on-year, to $12.94 million, beating the consensus of $11.65 million.
- Gross margin for the quarter improved 820 basis points to 21.3%, and the gross profit rose 65% to $2.7 million.
- Operating expenses declined 14.9% to $8.99 million.
- Operating loss for the quarter was $(6.2) million versus a loss of $(8.9) million last year.
- The company held $1.3 million in cash and equivalents as of Dec. 31, 2022.
- Adjusted EPS of $(0.13) missed the analyst consensus of $(0.12).
- “As we enter the back half of our fiscal year, we are focused on advancing our biofuel JV, with initial grain production expected in late calendar 2023, and developing the key centers of value we outlined previously,” said the management.
- Outlook, reiterated: S&W sees FY23 revenue of $80 million – $92 million versus an estimate of $86.85 million.
- The company expects FY23 adjusted EBITDA of $(7.0) million – $(2.0) million.
- Price action: SANW shares are trading lower by 9.53% at $1.80 on the last check Monday.
Catalyst Pharmaceuticals Announces Multiple Abstracts On FYCOMPA From Eisai Co, Ltd., To Be Presented At The 35th International Epilepsy Congress
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for
